Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial-Reference-Cited by-同舟云学术

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Published:2019-09-17 Issue:12 Volume:42 Page:2272-2281
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Rodbard Helena W.^ORCID,Rosenstock Julio^ORCID,Canani Luis H.,Deerochanawong Chaicharn,Gumprecht Janusz,Lindberg Søren Østergaard,Lingvay Ildiko^ORCID,Søndergaard Anette Luther,Treppendahl Marianne Bach,Montanya Eduard

Publisher

American Diabetes Association

Subject

Advanced and Specialised Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference36 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

4. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial;Ahrén;Lancet Diabetes Endocrinol,2017

5. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial;Aroda;Lancet Diabetes Endocrinol,2017

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin-based therapy: a new horizon in diabetes management;Journal of Diabetes & Metabolic Disorders;2024-08-17

2. Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice;Journal of Clinical Medicine;2024-08-13

3. Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study;Diabetes Therapy;2024-08-07

4. Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world;Frontiers in Pharmacology;2024-08-05

5. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus;Pharmacia;2024-08-02